Since 27 October, non-COVID-19-related research activities at Lausanne University Hospital (CHUV) involving collaborators with clinical duties have been put on hold in order to free human resources for patients care. Research projects related to COVID-19 and therapeutic clinical trials are continued and coordinated at the hospital services level.
The CTU Lausanne continues to support interventional and observational studies within the above framework. It supports local investigators participating in CanCovDia, a multicentric, randomised, double-blind, placebo-controlled trial sponsored and coordinated by the University Hospital Basel (Prof. M. Donath). The aim of the study is to evaluate Canakinumab's added value in patients with COVID-19 and Type 2 diabetes.
In parallel, the CTU carries on coordination for the SOLIDARITY trial consortium in Switzerland. The WHO published interim results of the international study in mid-October (see link to preprint below). The repurposed antiviral drugs Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon tested appeared to have little or no effect on hospitalised COVID-19 patients, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. An amendment to the protocol was recently submitted to the authorities to modify the tested treatments and add an immunomodulator drug as a new intervention arm. Remdesivir allocation will continue in order to close the debate on its efficacy. swissethics has already approved the amended protocol and the decision of Swissmedic is pending. The WHO is also evaluating the possibility of testing monoclonal antibodies in a future step.
Link to preprint, posted on 15 October 2020 on medRxiv:
Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results